Stock ABVC AMERICAN BRIVISION (HOLDING) CORPORATION
Add to a list
To use this feature you must be a member
Log inSign up
Inactive Instrument

American BriVision (Holding) Corporation Share Price OTC Markets

Equities

ABVC

US0247332069

Biotechnology & Medical Research

Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Exceptional extension!
Take advantage of the offer
* See conditions on site

Financials

Sales 2022 0.97 80.74 Sales 2023 0.15 12.69 Capitalization 89.51L 75Cr
Net income 2022 -1.6Cr -133.22Cr Net income 2023 -1Cr -83Cr EV / Sales 2022 2,42,08,439 x
Net Debt 2022 32.54L 27Cr Net Debt 2023 23.11L 19Cr EV / Sales 2023 7,38,80,417 x
P/E ratio 2022
-1.2 x
P/E ratio 2023
-0.48 x
Employees -
Yield 2022 *
-
Yield 2023
-
Free-Float 73.03%
More Fundamentals * Assessed data

Chart American BriVision (Holding) Corporation

Dynamic Chart

Latest news about American BriVision (Holding) Corporation

Abvc Biopharma, Inc. Enters into A Definitive Agreement with Oncox Biopharma, Inc CI
ABVC BioPharma, Inc., BioLite, Inc. and Rgene Corporation Enter Term Sheet with OncoX BioPharma, Inc CI
ABVC BioPharma, Inc. and BioFirst Corporation Enter Global Licensing Agreement with ForSeeCon Eye Corporation CI
ABVC BioPharma, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 CI
ABVC BioPharma Signs Licensing Deal With Senior Paradise MT
ABVC BioPharma, Inc. Executes a Definitive Agreement to Receive License Fees of $3 Million and Royalties of 2% on Future Revenue CI
ABVC BioPharma, Inc. announced that it has received $0.833333 million in funding from The Lind Partners, LLC CI
Top Premarket Decliners MT
Sector Update: Health Care Stocks Mixed Late Afternoon MT
Sector Update: Health Care MT
Traders Anticipate Fed Minutes as US Equity Futures Decline Pre-Bell MT
Top Midday Gainers MT
ABVC BioPharma, Inc. Announces Completion of Subject Treatment for Interim Analysis on ADHD Phase IIb Clinical Study CI
ABVC BioPharma, Inc. announced that it expects to receive $1 million in funding from The Lind Partners, LLC CI
ABVC BioPharma, Inc. Enters Definitive Agreement with Licensing Income Worth $467 Million and Royalties Up to $200 Million CI
More news

Analyst Recommendations on American BriVision (Holding) Corporation

Wall Street Set to Open Lower as Investors Await Fed Rate Hike MT
Maxim Downgrades ABVC Biopharma to Hold From Buy MT
Maxim Initiates Coverage on Abvc BioPharma With Buy Rating, $3 Price Target MT
More recommendations

Press releases American BriVision (Holding) Corporation

Promising Combination Therapy for Tripple Negative Breast Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, Potential Income of $13.75M and Royalties of up to $12.50M - Form 8-K PU
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M AQ
Combination Therapy Holds Promise for Pancreatic Cancer Treatment: A Milestone Collaboration Between ABVC and OncoX, ABVC Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M - Form 8-K PU
AiBtl BioPharma Inc. Acquired TT Life Company, Valued at $8.33M, With 1.66M AiBtl Shares at $5 per Share AQ
ABVC BioPharma Executes a Global Licensing Definitive Agreement for the Treatment of NSCLC, Expecting Aggregate Income of $13.75M and Royalties of up to $12.50M AQ
More press releases

Managers and Directors - American BriVision (Holding) Corporation

Managers TitleAgeSince
Uttam Yashwant Patil CEO
 Chief Executive Officer - 23/23/23
Leeds Chow DFI
 Director of Finance/CFO 35 01/21/01
Eugene Jiang CHM
 Chairman 38 01/15/01
Members of the board TitleAgeSince
Yue Min Chung BRD
 Director/Board Member 59 10/22/10
Shu Ling Chiang BRD
 Director/Board Member 68 -
Eugene Jiang CHM
 Chairman 38 01/15/01
More insiders

Company Profile

ABVC BioPharma, Inc. is a clinical-stage biopharmaceutical company focused on development products and technologies to combat various diseases. The Company develops its pipeline by tracking medical discoveries or medical device technologies in research institutions in the Asia-Pacific region. It has a pipeline of six drugs and one medical device under development. Its pipeline includes ABV-1504, ABV-1505, ABV-1601, ABV-1701, ABV-1519, and ABV-1703. ABV-1504 is a botanical reuptake inhibitor that targets norepinephrine to treat major depressive disorder (MDD). It is developing ABV-1505 for treating attention deficit hyperactivity disorder (ADHD). It has developed ABV-1601 for treating depression in cancer patients. ABV-1701 is a vitreous substitute for vitrectomy. Its ABV-1519 is used for the treatment of non-small cell lung cancer. ABV-1703 is a drug for advanced, inoperable, or metastatic pancreatic cancer. The Company develops drugs and medical devices derived from plants.
Sector
Biotechnology & Medical Research
Calendar
11/11/2024 - Q3 2024 Earnings Release (Projected)
More about the company

Sector Bio Therapeutic Drugs

1st Jan change Capi.
VERTEX PHARMACEUTICALS INCORPORATED Stock Vertex Pharmaceuticals Incorporated
+9.42% 11TCr
REGENERON PHARMACEUTICALS, INC. Stock Regeneron Pharmaceuticals, Inc.
+11.84% 11TCr
ARGENX SE Stock argenx SE
-2.56% 2.2TCr
BIONTECH SE Stock BioNTech SE
-14.15% 2.19TCr
GENMAB A/S Stock Genmab A/S
-5.29% 1.92TCr
BEIGENE, LTD. Stock BeiGene, Ltd.
-4.16% 1.81TCr
WUXI APPTEC CO., LTD. Stock WuXi AppTec Co., Ltd.
-38.29% 1.77TCr
NEUROCRINE BIOSCIENCES, INC. Stock Neurocrine Biosciences, Inc.
+7.99% 1.43TCr
SAREPTA THERAPEUTICS, INC. Stock Sarepta Therapeutics, Inc.
+36.24% 1.24TCr
Bio Therapeutic Drugs
  1. Stock Market
  2. Equities
  3. ABVC Stock
  4. ABVC Stock
-40% Exceptional extension: Our subscriptions help you unlock the best investment opportunities.
BENEFIT NOW